Vanguard Capital Management
HOWL icon

Vanguard Capital Management’s Werewolf Therapeutics HOWL Stock Holding History

Vanguard Capital Management’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.12M Hold
1,217,976
– – ﹤0.01% 3532
2026
Q2 		$438K Hold
1,217,976
– – ﹤0.01% 3729
2026
Q1 		$1.01M Buy
+1,217,976
New +$834K ﹤0.01% 3548

Other funds holding HOWL

DF
DC Funds Mclean, Virginia $741K AUM 2.77% 1-Year Est. Return
Jane Street
Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
HRT Financial
HRT Financial New York $57.2B AUM 52.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Covestor
Covestor London, United Kingdom $157M AUM 35.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Vanguard Capital Management's HOWL Position: Q3 2026 in Review

Vanguard Capital Management held its Werewolf Therapeutics (HOWL) position steady in Q3 2026 at 1,217,976 shares worth $1.12M. The position accounts for ﹤0.01% of the portfolio, ranked #3532.

Vanguard Capital Management first reported a position in HOWL in Q1 2026 and has held it in 3 quarters since. 30 funds tracked by Wall St. Rank hold HOWL as of Q3 2026.

  • Vanguard Capital Management held 1,217,976 shares of Werewolf Therapeutics worth $1.12M as of Q3 2026.
  • Vanguard Capital Management left its Werewolf Therapeutics share count unchanged in Q3 2026.
  • Werewolf Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #3532 holding.
  • Vanguard Capital Management first reported a position in Werewolf Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • 30 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.